Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. … It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

  2. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  3. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Sulfabenzamide

    go.drugbank.com/drugs/DB09355
    ApprovedWithdrawn

    Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.

  5. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.

  6. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.

  7. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).

  8. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]

  9. Drug

    Bismuth subcitrate potassium

    go.drugbank.com/drugs/DB09275
    ApprovedInvestigational

    A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).

  10. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

    Categories: Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid-Receptor Antagonist